Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Fabry disease].

S Feriozzi1, T Faraggiana

  • 1Centro di Riferimento Regionale Nefrologia e Dialisi, Ospedale Belcolle, Viterbo.

Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia
|January 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.

Molecular genetics and metabolism·2021
Same author

Redefining the Pulvinar Sign in Fabry Disease.

AJNR. American journal of neuroradiology·2017
Same author

Early markers of Fabry disease revealed by proteomics.

Molecular bioSystems·2015
Same author

[Guidelines: general principles and clinical application in nephrology].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2014
Same author

Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases.

Clinical genetics·2013
Same author

c-Flip overexpression affects satellite cell proliferation and promotes skeletal muscle aging.

Cell death & disease·2011
Same journal

[Rufus of Ephesus, On gout].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

A Case Report and Literature Review: Chlorhexidine-induced anaphylaxis in a hemodialysis patient.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

New Frontiers in the Treatment of Chronic Kidney Disease-associated Pruritus: A Case of Hemoperfusion with HA130.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

Fibronectin Glomerulopathy: A Case Report of Membranoproliferative Glomerulonephritis.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

Sodium Disorders in Multiple Myeloma: Beyond Pseudohyponatremia to Clinical Pitfalls and Mechanistic Insights.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
Same journal

Acute Kidney Injury and Early Diagnostic Biomarkers: A Narrative Literature Review.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2026
See all related articles

Anderson-Fabry disease, a rare genetic disorder, results from alpha-galactosidase A deficiency. Enzyme replacement therapy offers positive outcomes, and ongoing research aims to further validate its effectiveness.

Area of Science:

  • Genetics and Hereditary Diseases
  • Biochemistry
  • Enzymology

Context:

  • Anderson-Fabry disease is an X-linked hereditary disorder caused by alpha-galactosidase A deficiency.
  • Glycosphingolipid accumulation in organs like vessels, heart, and kidneys characterizes the disease.
  • Lysosomal membrane damage and impaired cellular metabolism are key histological features.

Purpose:

  • To evaluate the efficacy of enzyme replacement therapy (ERT) for Anderson-Fabry disease.
  • To analyze clinical data and histological findings in patients undergoing ERT.
  • To contribute to the ongoing verification of ERT's long-term validity.

Summary:

  • ERT involves administering recombinant alpha-galactosidase A to counteract enzyme deficiency.
  • Prior to ERT, the disease course was typically fatal, leading to early death from stroke or kidney failure.

Related Experiment Videos

  • This study presents observational data to support the clinical benefits of ERT.

    • Impact:

    • Provides evidence supporting the use of enzyme replacement therapy for Anderson-Fabry disease.
    • Highlights the potential for improved patient outcomes and quality of life.
    • Contributes to a better understanding of the disease's progression and therapeutic interventions.